Literature DB >> 12853447

Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes.

Anjali Pawar1, Donald B Jump.   

Abstract

Peroxisome proliferator-activated receptors (PPARs alpha, beta, gamma1, and gamma2) are widely regarded as monitors of intracellular nonesterified fatty acid (NEFA) levels. As such, fatty acid binding to PPAR leads to changes in the transcription of many genes involved in lipid metabolism and storage. Although the composition of the intracellular NEFA pool is likely an important factor controlling PPAR activity, little information is available on factors affecting its composition. Accordingly, we have examined the effects of exogenous fatty acids on PPARalpha activity and NEFA pool composition in rat primary hepatocytes. Prior to the addition of fatty acids to primary hepatocytes, nonesterified unsaturated fatty acid levels are very low, representing </=0.5% of the total fatty acid in the cell. The relative abundance of putative PPARalpha ligands in the NEFA pool is 20:4n-6 = 18:2n-6 = 18:1n-9 > 22:6n-3 > 18:3n-3/6 = 20:5n-3. Of these fatty acids, only 20:5n-3 and 22:6n-3 consistently induced PPARalpha activity. Metabolic labeling of primary hepatocytes indicated that both 14C-18:1n-9 and 14C-20:5n-3 are rapidly assimilated into neutral and polar lipids. Although the addition of 18:1n-9 had no effect on NEFA pool composition, 20:5n-3 mass increased >15-fold within 90 min. Changes in NEFA pool 20:5n-3 mass correlated with dynamic changes in the PPARalpha-regulated transcript mRNACYP4A. Metabolic labeling also indicated that a significant fraction of 14C-20:5n-3 was elongated to 22:5n-3. Cells treated with 22:5n-3 or 22:6n-3 led to a significant accumulation of 20:5n-3 in the NEFA pool through a process that requires peroxisomal beta-oxidation and fatty acyl CoA thioesterase activity. Further analyses suggest that 20:5n-3 and 22:6n-3, but not 22:5n-3, are active ligands for PPARalpha. These studies suggest that basal fatty acid levels in the NEFA pool coupled with rates of fatty acid esterification, elongation, desaturation, peroxisomal beta-oxidation, and fatty acyl thioestease activity are important determinants controlling NEFA pool composition and PPARalpha activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853447     DOI: 10.1074/jbc.M306238200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.

Authors:  Holly A Cyphert; Xuemei Ge; Alison B Kohan; Lisa M Salati; Yanqiao Zhang; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

2.  Effects of albumin-bound-fatty acids on the growth of the human T lymphoblastic cell line Jurkat.

Authors:  Toshio Okazaki; Tetsumi Iwasaki; Akemi Fukuoka; Mitsuyuki Suzuki; Hiroshi Katagiri; Tetsuroh Okano; Shinichiro Takahashi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-10-01       Impact factor: 2.416

3.  A short-term n-3 DPA supplementation study in humans.

Authors:  Eliza Miller; Gunveen Kaur; Amy Larsen; Su Peng Loh; Kaisa Linderborg; Harrison S Weisinger; Giovanni M Turchini; David Cameron-Smith; Andrew J Sinclair
Journal:  Eur J Nutr       Date:  2012-06-23       Impact factor: 5.614

Review 4.  (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Nutr       Date:  2012-01-25       Impact factor: 4.798

5.  Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation.

Authors:  Donald B Jump; Moises Torres-Gonzalez; L Karl Olson
Journal:  Biochem Pharmacol       Date:  2010-12-22       Impact factor: 5.858

Review 6.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

7.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

Review 8.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

Review 9.  Fatty acid-regulated transcription factors in the liver.

Authors:  Donald B Jump; Sasmita Tripathy; Christopher M Depner
Journal:  Annu Rev Nutr       Date:  2013-03-22       Impact factor: 11.848

Review 10.  Docosahexaenoic acid (DHA) and hepatic gene transcription.

Authors:  Donald B Jump; Daniela Botolin; Yun Wang; Jinghua Xu; Olivier Demeure; Barbara Christian
Journal:  Chem Phys Lipids       Date:  2008-02-23       Impact factor: 3.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.